Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director | May 16, 2017 | May 18, 2017 |
| TriSalus Life Sciences, Inc.MTAC · Entity 5872 | Director | March 18, 2021 | March 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PULSE BIOSCIENCES, INC.
Report date May 16, 2017 · Filed May 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.14 · Expires 2027-05-16 | Direct | 15,000 |
Reported balance
After 2017-05-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-16 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option will vest in equal monthly installments over a one year period that will begin on June 1, 2017, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one year period that will begin on June 1, 2017, subject to the Reporting Person's continued service through each vesting date.
TriSalus Life Sciences, Inc.
Report date March 18, 2021 · Filed March 22, 2021
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2017 Filed May 18, 2017 16:08 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.14 | $0.00 |
DisclosureSEC source: 0001209191-17-033571 · doc4.xml · derivative · entry 1 Thaure Thierry B. · CIK 0001674555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period that will begin on June 1, 2017, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 12, 2017 Filed May 12, 2017 18:17 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001209191-17-032134 · doc4.xml · derivative · entry 4 Thaure Thierry B. · CIK 0001674555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,655 Underlying: Common Stock · 10,000 shares Expires 2020-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a three year period commencing on June 1, 2015 and ending on March 1, 2018, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 12, 2017 Filed May 12, 2017 18:17 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 5,000 | $24.90 | $124,500.00 |
DisclosureSEC source: 0001209191-17-032134 · doc4.xml · nonDerivative · entry 3 Thaure Thierry B. · CIK 0001674555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 12, 2017 Filed May 12, 2017 18:17 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 5,000 | $23.90 | $119,500.00 |
DisclosureSEC source: 0001209191-17-032134 · doc4.xml · nonDerivative · entry 2 Thaure Thierry B. · CIK 0001674555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 12, 2017 Filed May 12, 2017 18:17 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 10,000 | $2.67 | $26,700.00 |
DisclosureSEC source: 0001209191-17-032134 · doc4.xml · nonDerivative · entry 1 Thaure Thierry B. · CIK 0001674555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2017 Filed May 10, 2017 17:58 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001209191-17-031389 · doc4.xml · derivative · entry 3 Thaure Thierry B. · CIK 0001674555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,655 Underlying: Common Stock · 15,000 shares Expires 2020-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a three year period commencing on June 1, 2015 and ending on March 1, 2018, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 08, 2017 Filed May 10, 2017 17:58 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | SaleCommon Stock | 15,000 | $22.49 | $337,320.00 |
DisclosureSEC source: 0001209191-17-031389 · doc4.xml · nonDerivative · entry 2 Thaure Thierry B. · CIK 0001674555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This is the weighted average purchase price of the shares, which ranged from $22.00 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 08, 2017 Filed May 10, 2017 17:58 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 15,000 | $2.67 | $40,050.00 |
DisclosureSEC source: 0001209191-17-031389 · doc4.xml · nonDerivative · entry 1 Thaure Thierry B. · CIK 0001674555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.